Shantha Biotechnics Limited   Report issue

For profit Phase 2 Phase 3 Phase 4
Founded: Hyderabad India (1993)
Status: Acquired by Sanofi-Aventis (2009)

Organization Overview

First Clinical Trial
2005
NCT00119197
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Shantha Biotechnics Limited, Hyderabad, India

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cholera (Phase 4)

Diarrhea (Phase 3)

Diphtheria (Phase 4)

Gastroenteritis (Phase 2)

Hepatitis (Phase 4)

Hepatitis A (Phase 4)

Hepatitis B (Phase 4)

Neutropenia (Phase 3)

Rotavirus Infections (Phase 2)

Tetanus (Phase 4)

Tetany (Phase 4)

Vibrio Infections (Phase 3)

Whooping Cough (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 15
  • # of Trial APIs: 7